Valvular Aortic valve articles

Intermedia Risk Patients evidence for TAVR

SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio

SOLACI CACI | TAVI: Evidencia para pacientes de riesgo intermedio

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Oscar Méndiz, entitled “TAVI: Evidencia para pacientes de riesgo intermedio”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

SOLACI CACI 2017 | Present and Future Transcatheter Management of Mitral Insufficiency

Read articles on the main presentations of the second day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Gregg Stone, entitled “Present and Future Transcatheter Management of Mitral Insufficiency”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

SOLACI CACI 2017 | Clinical results of Mitraclip in degenerative mitral valve regurgitation

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Clinical results of Mitraclip in degenerative mitral valve regurgitation”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

cardiovascular health

SOLACI CACI 2017 | Role of embolic protection during Transcatheter Aortic valve replacement

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Samir Kapadia, entitled “Role of embolic protection during Transcatheter Aortic valve replacement”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

valvula-mitral-protesica

SOLACI CACI 2017 | The Mitral Revolution: Emerging Data and Future Trends

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Juan Granada entitled “The Mitral Revolution: Emerging Data and Future Trends”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

SOLACI CACI 2017 | New horizons in percutaneous mitral valve implantation

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Eduardo de Marchena, entitled “New horizons in percutaneous mitral valve implantation”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

SOLACI CACI 2017 | When and how to interving patients with CAD undergoing TAVI

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress. See the presentation by Dr. Fabio Sandoli, entitled “When and how to interving patients with CAD undergoing TAVI”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Role of general avestesia- Baumbach

SOLACI CACI 2017 | Role of general anesthesia compare to conscious sedation during TAVR

Read articles on the main presentations of the first day of SOLACI-CACI 2017 Congress.  Check the presentation of Dr. Andreas Baumbach, entitled “Role of general anesthesia compare to conscious sedation during TAVR”. We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

Doble antiagregación en TAVI, simple es mejor?

Dual Antiplatelet in TAVR: Is Single Better?

Courtesy of Dr. Agustín Vecchia. As TAVR is expanded to lower risk patients, complications become more relevant. As regards stroke, the PARTNER 2 and SURTAVI one year outcomes are 8.0% and 8.2% respectively. The mechanisms behind this complication have not yet been clarified and, therefore, neither have guideline recommendations in this regard (as we can tell

Lotus vs Sapien 3, mecanismos diferentes con resultados similares

Lotus vs Sapien 3, different mechanisms with similar results

The new generation devices for transfemoral transcatheter aortic valve replacement have been optimized to improve valve position and reduce residual aortic regurgitation.   This study compared 30 day, 12 month and 24 month outcomes of the repositionable, Lotus valve, with controlled mechanical expansion, and the balloon-expandable valve Edwards Sapien 3.   Primary end point was all cause mortality

¿Cómo clasificar la estenosis aórtica de los pacientes que recibieron TAVI?

How can we classify aortic stenosis in patients who underwent TAVR?

Courtesy of Dr. Carlos Fava. Aortic stenosis can present different hemodynamic patterns, such as low flow and low gradient with reduced or preserved ventricular function. However, evidence on the evolution of different hemodynamic patterns after transcatheter aortic valve replacement (TAVR) is limited. This study consisted in a retrospective analysis of 368 patients who underwent TAVR. The population was divided in

Top